1-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea → 1-{3-tert-Butyl-1'-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1'H-[1,4']bipyrazolyl-5-yl}-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea
Reaction equation
ClC(Cl)(Cl)CO[C:5](=[O:31])[NH:6][C:7]1[N:11]([C:12]2[CH:13]=[N:14][N:15]([CH2:17][CH2:18][CH2:19][O:20][CH:21]3[CH2:26][CH2:25][CH2:24][CH2:23][O:22]3)[CH:16]=2)[N:10]=[C:9]([C:27]([CH3:30])([CH3:29])[CH3:28])[CH:8]=1.C(C1C=C(NC([NH:54][C@@H:55]2[C:64]3[C:59](=[CH:60][CH:61]=[CH:62][CH:63]=3)[C@H:58]([O:65][C:66]3[CH:67]=[CH:68][C:69]4[N:70]([C:72]([N:75]5[CH2:80][CH2:79][CH2:78][CH2:77][CH2:76]5)=[N:73][N:74]=4)[CH:71]=3)[CH2:57][CH2:56]2)=O)N(C2C=CC(CO)=CC=2)N=1)(C)(C)C>>[C:27]([C:9]1[CH:8]=[C:7]([NH:6][C:5]([NH:54][C@@H:55]2[C:64]3[C:59](=[CH:60][CH:61]=[CH:62][CH:63]=3)[C@H:58]([O:65][C:66]3[CH:67]=[CH:68][C:69]4[N:70]([C:72]([N:75]5[CH2:76][CH2:77][CH2:78][CH2:79][CH2:80]5)=[N:73][N:74]=4)[CH:71]=3)[CH2:57][CH2:56]2)=[O:31])[N:11]([C:12]2[CH:13]=[N:14][N:15]([CH2:17][CH2:18][CH2:19][O:20][CH:21]3[CH2:26][CH2:25][CH2:24][CH2:23][O:22]3)[CH:16]=2)[N:10]=1)([CH3:30])([CH3:28])[CH3:29]Participants
3
Reactant 2
HCID 716036691-[5-tert-Butyl-2-(4-hydroxymethyl-phenyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-piperidin-1-yl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea
HCID 86687181{3-tert-Butyl-1'-[3-(tetrahydro-pyran-2-yloxy)-propyl]-1'H-[1,4']bipyrazolyl-5-yl}-carbamic acid 2,2,2-trichloro-ethyl esterProduct 1
Procedure
The title compound was prepared starting from Intermediate 3c and Intermediate 113c using analogous procedures to those described in Intermediate 106a. LCMS (Method 4): Rt 3.34 min, m/z 737 [MH+].
Sources & evidence
- ORD record
- ord-8544d988c15344df8965841fd851ebfb
- Source dataset
- uspto-grants-2016_04
- Patent number
- US09315503B2
Reaction notes
Loading…